← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksABOSRevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

ABOS logoAcumen Pharmaceuticals, Inc. (ABOS) Revenue History

Annual and quarterly revenue from 2019 to 2024

TTM Revenue
$0
0
YoY Growth
-
Latest Quarter
$0
Q3 2025
QoQ Growth
-

Compound Annual Growth Rate (CAGR)

3-Year-
5-Year-
10-Year-
Highest Annual Revenue$1.7M (2019)
Highest Quarter$329K (Q4 2020)

Loading revenue history...

ABOS Revenue Growth

1-Year Growth
-
3-Year CAGR
-
5-Year CAGR
-
10-Year CAGR
-
TTM vs Prior Year-
Peak Annual Revenue$1.7M (2019)

Download Historical Data

6 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

ABOS Revenue Analysis (2019–2024)

As of May 8, 2026, Acumen Pharmaceuticals, Inc. (ABOS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.

Looking at the longer-term picture, ABOS's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $1.7 million in 2019.

When compared to Healthcare sector peers including ACIU (-86.9% YoY). Compare ABOS vs ACIU →

ABOS Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
ABOS logoABOSCurrent$0---
ACIU logoACIU$4M-86.9%-25.4%-1927.3%
Best in groupLowest in group

ABOS Historical Revenue Data (2019–2024)

Showing 6 of 6 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2024$0-$0-$-114,017,000-
2023$0-$0-$-61,138,000-
2022$0-$0-$-45,237,000-
2021$0-100.0%$-12,305,000-$-19,584,000-
2020$1.4M-15.4%$-6,561,000-456.9%$-7,912,000-551.0%
2019$1.7M-$-6,879,000-405.4%$-7,805,000-459.9%

See ABOS's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is ABOS Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare ABOS vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

ABOS — Frequently Asked Questions

Quick answers to the most common questions about buying ABOS stock.

Is ABOS's revenue growth accelerating or slowing?

ABOS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is ABOS's long-term revenue growth rate?

Acumen Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.

How is ABOS's revenue distributed by segment?

ABOS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2024 are available for download. Segment mix reveals concentration and diversification trends.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

ABOS Revenue Over Time (2019–2024)